UNIVERSITY OF SYDNEY

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Established: 1850-01-01

Employees: -

Market Cap: -

Website: https://www.sydney.edu.au/

Clinical Trials

Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination

Phase 1

Conditions: Complication of Transplant

Interventions: Biological: T-cell infusion, influenza vaccination

First Posted Date: 2016-07-25

Last Posted Date: 2016-11-22

Lead Sponsor: University of Sydney

Target Recruit Count: 12

Registration Number: NCT02843321

Locations: 🇦🇺
Westmead Hospital Department of Haematology, Westmead, Sydney, New South Wales, Australia

Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

Phase 4

Recruiting

Conditions: End-Stage Kidney Disease

Interventions: Other: Default dialysate sodium concentration of 140mmol/l
Other: Default dialysate sodium concentration of 137mmol/l

First Posted Date: 2016-07-06

Last Posted Date: 2024-06-07

Lead Sponsor: University of Sydney

Target Recruit Count: 50000

Registration Number: NCT02823821

Locations: 🇦🇺
Sunshine Coast University Private Hospital, Birtinya, Australia
🇩🇪
KfH Nierenzentrum Lichtenfels, Lichtenfels, Germany
🇲🇾
Hospital Sultanah Aminah, Johor Bahru, Malaysia

and more 253 locations

Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation

Phase 1

Conditions: Adenovirus
CMV Infection
EBV

Interventions: Biological: Virus specific CTLs

First Posted Date: 2016-05-20

Last Posted Date: 2016-07-21

Lead Sponsor: University of Sydney

Target Recruit Count: 25

Registration Number: NCT02779439

Locations: 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia

The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?

Not Applicable

Completed

Conditions: Preterm Birth

Interventions: Procedure: Deferred cord clamping

First Posted Date: 2015-11-17

Last Posted Date: 2020-11-05

Lead Sponsor: University of Sydney

Target Recruit Count: 1637

Registration Number: NCT02606058

Locations: 🇺🇸
University of Vermont Medical Centre, Burlington, Vermont, United States
🇦🇺
Royal Hospital for Women, Sydney, New South Wales, Australia
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 23 locations

Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B

Phase 3

Completed

Conditions: Cancer

Interventions: Drug: Methoxyflurane
Drug: Placebo

First Posted Date: 2015-11-13

Last Posted Date: 2020-05-11

Lead Sponsor: University of Sydney

Target Recruit Count: 420

Registration Number: NCT02604225

Locations: 🇦🇺
Australian Clinical Trials, Wahroonga, New South Wales, Australia
🇦🇺
Concord Hospital, Concord, New South Wales, Australia
🇦🇺
Westmead Hospital, Westmead, Australia

and more 4 locations

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Phase 3

Conditions: Germ Cell Tumor

Interventions: Drug: Etoposide
Drug: Cisplatin
Drug: Pegylated G-CSF (Pegfilgrastim)
Drug: Filgrastim

First Posted Date: 2015-10-21

Last Posted Date: 2021-11-29

Lead Sponsor: University of Sydney

Target Recruit Count: 500

Registration Number: NCT02582697

Locations: 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 25 locations

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: Conventional NSAA
Drug: Enzalutamide
Drug: LHRHA
Radiation: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)

First Posted Date: 2015-05-18

Last Posted Date: 2024-02-13

Lead Sponsor: University of Sydney

Target Recruit Count: 802

Registration Number: NCT02446444

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇦🇺
Campbelltown Hospital, Campbelltown, New South Wales, Australia

and more 65 locations

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: NSAA
Drug: Enzalutamide
Drug: LHRHA or Surgical Castration

First Posted Date: 2015-05-18

Last Posted Date: 2022-11-30

Lead Sponsor: University of Sydney

Target Recruit Count: 1125

Registration Number: NCT02446405

Locations: 🇨🇦
BCCA Vancouver Centre, Vancouver, British Columbia, Canada
🇦🇺
Australian Urology Associates, Malvern, Victoria, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia

and more 79 locations

Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)

Phase 4

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: Aflibercept
Procedure: Targeted laser therapy

First Posted Date: 2015-05-04

Last Posted Date: 2022-05-31

Lead Sponsor: University of Sydney

Target Recruit Count: 48

Registration Number: NCT02432547

Locations: 🇦🇺
Centre for Eye Research Australia, Melbourne, Victoria, Australia
🇦🇺
Save Sight Institute, Sydney, New South Wales, Australia

Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction Monitoring

Phase 2

Conditions: Prostate Cancer

Interventions: Radiation: Multi-fraction SABR

First Posted Date: 2015-03-24

Last Posted Date: 2017-06-22

Lead Sponsor: University of Sydney

Target Recruit Count: 48

Registration Number: NCT02397317

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺
Calvary Mater Newcastle, Newcastle, New South Wales, Australia
🇦🇺
Liverpool Cancer Therapy Centre, Sydney, New South Wales, Australia

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy